A systematic review of the psychiatric side-effects of efavirenz

AIDS and Behavior

Volumn 15, Issue 8, 2011, Pages 1803-1818

  Kenedi, Christopher A ^a,b   Goforth, Harold W ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Affective disorders; Anxiety; Depression; Efavirenz; HIV; Insomnia; Mania; Neuropsychiatric; Nightmares; Side effects; Suicide; Sustiva

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; EFAVIRENZ;

CHEMICALLY INDUCED DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MENTAL DISEASE; PSYCHOLOGICAL ASPECT; REVIEW;

ANTI-HIV AGENTS; BENZOXAZINES; HIV INFECTIONS; HUMANS; MENTAL DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84555203868     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-9939-5     Document Type: Review

References (67)

1. Gallant JE, DeJesus E, Arribas JR, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-60. (Pubitemid 43113030)
2. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: A systematic review. Clin Infect Dis. 2003;36(9):1186-90. (Pubitemid 36549642)
3. Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: A review. Expert Opin Pharmacother. 2007;8(6):851-71. (Pubitemid 46736458)
4. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV- 1-Infected Adults and Adolescents. Available from http://AIDSinfo.nih.gov. Cited Accessed, 1 May 2009.
5. Sustiva [efavirenz;productinformation].Wilmington, Delaware: DuPont Pharmaceuticals. http://packageinserts.bms.com/pi/pi-sustiva.pdf.
6. Ruiz N. Clinical history of efavirenz. Int J Clin Pract Suppl. 1999;103:3-7. (Pubitemid 29341321)
7. Moyle G. In: 6th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 17-21, 2002.
8. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009; 11(2):103-9.
9. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29(3):244-53. (Pubitemid 34208532)
10. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: A randomized trial. Ann Intern Med. 2009; 151(3):149-56.
11. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: A cross-sectional case control study. HIV Med. 2006;7(8):544-8. (Pubitemid 44742355)
12. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999; 341(25):1865-73.
13. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38(5):560-5. (Pubitemid 40524478)
14. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714-21.
15. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003;188(5):625-34. (Pubitemid 37115174)
16. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials. 2002;3(4):279-86.
17. MedWatchUSFaDA. http://wwwfdagov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM16- 4871pdf. Accessed 7 December 2010.
18. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2008. p. 701.
19. Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(3):257-64. (Pubitemid 40923204)
20. Goldenberg D. Psychiatric and neuropsychiatric manifestations of HIV infection. J Int Assoc Physicians AIDS Care (Chic Ill). 2003;2(2):88. author reply 9-90.
21. Wanchu APS, Bambery P, Singh S, Varma S. Adverse drug reactions to generic antiretroviral medications in resource constrained set- tings: Implication for scaling up therapy. In: Paper presented at 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006 (abstract 562).
22. Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4(1):62-6. (Pubitemid 37161538)
23. Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: A substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42(12):1790-9. (Pubitemid 43839448)
24. O'Mahony SM, Myint AM, Steinbusch H, et al. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation. 2005;12(5):293-8. (Pubitemid 41318212)
25. Moreno A, Labelle C, Samet JH. Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: A report of two cases. HIV Med. 2003;4(3): 302-4. (Pubitemid 36949888)
26. Damsa C, Bandelier C, Maris S, et al. Recurrence of post-traumatic stress disorder and antiretrovirals. Scand J Infect Dis. 2005; 37(4):313-6. (Pubitemid 40542784)
27. Shah MD, Balderson K. A manic episode associated with efavirenz therapy for HIV infection. AIDS. 2003;17(11):1713-4. (Pubitemid 36951700)
28. Peyriere H, Mauboussin JM, Rouanet I, et al. Management of sudden psychiatric disorders related to efavirenz. AIDS. 2001; 15(10):1323-4. (Pubitemid 32592372)
29. Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis. 2004;38(3):430-2. (Pubitemid 38200124)
30. Tashima K, Staszewski S, Nelson M, et al. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. 2008;22(2):275-9.
31. Faggian F, Lattuada E, Lanzafame M, et al. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients. AIDS Care. 2005;17(7):908-10. (Pubitemid 41284704)
32. Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenzinduced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials. 2003;4(3):145-9. (Pubitemid 36748619)
33. Garey M, editor. Efavirenz (EFV) tolerability in the real world: Relation to mental illness, alcohol, and illicit drug use in a large, urban HIV clinic. In: Presented at the XIII international AIDS conference, Durban, SA, July 9-14, 2000 (abstract no. WePeB4288).
34. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51(3):213-7. (Pubitemid 32391497)
35. Marwaha A. Getting high on HIV drugs in South Africa. http://newsbbccouk/2/hi/africa/7768059stm. 2008. Accessed 7 December 2010.
36. Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2008;49(1):61-3.
37. Bickel M, Stephan C, Rottmann C, et al. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand J Infect Dis. 2005;37(6-7):520-2. (Pubitemid 41038530)
38. Gill MJ, Rachlis A, Walmsley S, et al. Canadian Expert Panel recommendations on the management of CNS symptoms related to efavirenz. Can J Infect Dis. 2001;12:20c-30c. (Pubitemid 33761508)
39. Skeie L, Maeland A. Can efavirenz be taken in the morning? Scand J Infect Dis. 2006;38(11-12):1089-91. (Pubitemid 44869286)
40. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther. 2005;10(4):489-98. (Pubitemid 41059195)
41. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391-400. (Pubitemid 40065906)
42. van Luin M, Brouwer AM, van der Ven A, et al. Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. AIDS. 2009;23(6):742-4.
43. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr. 2006;43(3):284-92. (Pubitemid 44674008)
44. Martinez-Picado J, Negredo E, Ruiz L, et al. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med. 2003;139(2):81-9.
45. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011-9. (Pubitemid 38989366)
46. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet. 2004;363 (9417):1253-63. (Pubitemid 38496486)
47. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6(4): 187-96. (Pubitemid 41601130)
48. Spire B, Carrieri P, Garzot MA, et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16(5):558-64. (Pubitemid 38918087)
49. Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27(4):336-43. (Pubitemid 32729079)
50. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr. 2006;42(4):514-5. (Pubitemid 44050905)
51. Brokaw DK, Fulco PP, Klinger R. Efavirenz use in HIV infected patients with a psychiatric history. In: Presented at the 35th American Society of Health-System Pharmacists annual mid-year clinical meeting, Las Vegas, NV, December 3-7, 2000.
52. Gaughan DM, Hughes MD, Oleske JM, et al. Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics. 2004;113(6):e544-51.
53. Goldenberg D, Boyle B, Vaamonde C, et al., editors. Psychiatric illness and efavirenz study (PIES). In: Presented at the XIII international AIDS conference, Durban, SA, July 9-14, 2000.
54. Jena A, Sachdeva RK, Sharma A, et al. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic Ill). 2009;8(5):318-22.
55. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006;20(8):542-8. (Pubitemid 44769201)
56. Welch KJ, Morse A. Association between efavirenz and selected psychiatric and neurological conditions. J Infect Dis. 2002;85(2): 268-9. (Pubitemid 34056454)
57. Koppel BS, Bharel C. Use of amitriptyline to offset sleep disturbances caused by efavirenz. AIDS Patient Care STDS. 2005; 19(7):419-20. (Pubitemid 41105520)
58. de la Garza C, Paoletti-Duarte, García-Martín, et al. Efavirenzinduced psychosis. AIDS. 2001;15(14):1911-2.
59. Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007;45(10):e128-30. (Pubitemid 351411927)
60. Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis. 2005;40(3):e22-3.
61. Poulsen HD, Lublin HK. Efavirenz-induced psychosis leading to involuntary detention. AIDS. 2003;17(3):451-3. (Pubitemid 36223276)
62. Allavena C, Le Moal G, Michau C, et al. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: A report of nine cases. Antivir Ther. 2006; 11(2):263-5.
63. Dawson S, Woods C. Neuropsychiatric effects of efavirenz: Delayed onset. Int J STD AIDS. 2005;16(11):769-70. (Pubitemid 41659543)
64. Puzantian T. Central nervous system adverse effects with efavirenz: Case report and review. Pharmacotherapy. 2002;22(7): 930-3. (Pubitemid 34743443)
65. Sabato S, Wesselingh S, Fuller A, et al. Efavirenz-induced catatonia. AIDS. 2002;16(13):1841-2.
66. Blanch J, Corbella B, Garcia F, et al. Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 2001;33(2):270-1. (Pubitemid 32643349)
67. Boscacci RT, Buclin T, Furrer H, et al. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006;20(9): 1352-4. (Pubitemid 44030397)